Author Interviews, Biomarkers, Cancer Research / 28.06.2020
Guardant Health’s LUNAR-2 Assay: A Big Step Toward Liquid Biopsy Diagnosis of Colon Cancer
MedicalResearch.com Interview with:
Dr. Kathryn Lang
VP, Outcomes and Evidence
Guardant Health
MedicalResearch.com: What is the background for this study?
Response: Despite a wide variety of screening methods available and increasing public awareness of the value of early detection, colorectal cancer (CRC) remains a leading cause of cancer-related deaths. However nearly 1 in 3 adults in the United States is not compliant with screening recommendations, with most citing that current screening methods are time consuming, unpleasant (stool-based testing), and in the case of colonoscopy, invasive. A blood-based CRC screening test could improve compliance rates by providing physicians with an opportunistic, in-office screening modality. However, demonstrating the clinical utility of blood-based cell-free circulating tumor DNA (ctDNA) fractions for the detection of cancer in asymptomatic individuals has thus far been challenged by the failure to achieve clinically meaningful sensitivity and specificity thresholds due to significantly lower tumor cell-free free DNA fractions and the increasing relevance of biological confounders.
The multi-modal approach of Guardant Health’s LUNAR-2 assay (genomics, methylation and fragmentomics) coupled with advanced bioinformatic analysis and a focused approach of honing in on the unique signals of CRC has been shown in previously reported cohorts to perform with sensitivity and specificity which satisfies the needs of clinicians in screening for CRC. (more…)